Abeona Therapeutics Inc (NASDAQ:ABEO – Get Free Report) CFO Joseph Walter Vazzano purchased 5,608 shares of the business’s stock in a transaction dated Thursday, April 25th. The shares were purchased at an average cost of $3.14 per share, for a total transaction of $17,609.12. Following the completion of the purchase, the chief financial officer now directly owns 233,868 shares of the company’s stock, valued at approximately $734,345.52. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Abeona Therapeutics Trading Up 2.2 %
Shares of ABEO stock opened at $3.26 on Friday. The stock has a 50 day simple moving average of $7.31 and a two-hundred day simple moving average of $5.61. Abeona Therapeutics Inc has a fifty-two week low of $2.83 and a fifty-two week high of $9.01.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last released its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, analysts forecast that Abeona Therapeutics Inc will post -2.05 earnings per share for the current year.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on Abeona Therapeutics
Institutional Investors Weigh In On Abeona Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $199,000. Worth Venture Partners LLC boosted its position in shares of Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 121,969 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Abeona Therapeutics by 84.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock valued at $13,682,000 after buying an additional 1,488,834 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics during the third quarter valued at approximately $648,000. Finally, AIGH Capital Management LLC boosted its position in shares of Abeona Therapeutics by 77.7% during the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock valued at $4,779,000 after buying an additional 496,278 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
- Five stocks we like better than Abeona Therapeutics
- How to Invest in Blue Chip Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Stocks Leading the U.S. Agriculture Comeback
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.